

# CorNotes

## CVI SEMINAR SERIES

No CVI Seminars will be held during July or August. We are also planning CVI seminars for the Fall. If you would like to host a speaker, please contact Dr. Cribbs at x72817.

## CVI JOURNAL CLUB

July 10.....Mr. Krishnamurthy  
August 14.....Dr. Coaxum

For further information, contact Dr. Byron at x72819.

## RECENT PUBLICATIONS FROM THE CVI

Godmundsson, G.S., Ohr, J., Leya, F., Jacobs, W.R., Godwin, J.E., Schwartz, J. An unusual case of recurrent Löffler endomyocarditis of the aortic valve. *Arch. Pathol. Lab. Med.* 127(5):606-609, 2003.

Luke, A., Wu, X.D., Zhu, X.F., Kan, D.H., Su, Y., Cooper, R. Linkage for BMI at 3q27 region confirmed in an African-American population. *Diabetes* 52(5):1284-1287, 2003.

Zhu, X.F., Chang, Y.P.C., Yan, D., Weder, A., Cooper, R., Luke, A., Kan, D.H., Chakravarti, A. Associations between hypertension and genes in the renin-angiotensin system. *Hypertension* 41(5):1027-1034, 2003.

Ahmad, S., Bacher, H.P., Lassen, M.R., Hoppensteadt, D.A., Leitz, H., Misselwitz, F., Walenga, J.M., Fareed, J. Investigations of the immunoglobulin subtype transformation of anti-heparin-platelet factor 4 antibodies during treatment with a low-molecular-weight heparin (clivarin) in orthopedic patients. *Arch. Pathol. Lab. Med.* 127(5):584-588, 2003.

Maier, L.S., Zhang, T., Chen, L., DeSantiago, J., Brown, J.H., Bers, D.M. Transgenic CaMKII $\delta_c$  overexpression uniquely alters cardiac myocyte Ca<sup>2+</sup> handling - reduced SR Ca<sup>2+</sup> load and activated SR Ca<sup>2+</sup> release. *Circ. Res.* 92(8):904-911, 2003.

Zhang, T., Maier, L.S., Dalton, N.D., Miyamoto, S., Ross, J., Jr., Bers, D.M., Brown, J.H. The  $\delta_c$  isoform of CaMKII is activated in cardiac hypertrophy and induces dilated cardiomyopathy and heart failure. *Circ. Res.* 92(8):912-919, 2003.

Erzurum, V.Z., Bian, J.F., Husak, V.A., Ellinger, J., Xue, L., Burgess, W.H., Greisler, H.P. R136K fibroblast growth factor 1

mutant induces heparin-independent migration of endothelial cells through fibrin glue. *J. Vasc. Surg.* 37(5):1075-1081, 2003.

Weber, C.R., Ginsburg, K.S., Bers, D.M. Cardiac submembrane [Na<sup>+</sup>] transients sensed by Na<sup>+</sup>-Ca<sup>2+</sup> exchange current. *Circ. Res.* 92(9):950-952, 2003.

Ramos, J., Jung, W.Y., Ramos-Franco, J., Mignery, G.A., Fill, M. Single channel function of inositol 1,4,5-trisphosphate receptor type-1 and -2 isoform domain-swap chimeras. *J. Gen. Physiol.* 121(5):399-411, 2003.

## NEW CVI GRANTS AND CONTRACTS

Glaxo SmithKline (King of Prussia, PA) - investigations on the inflammatory response as a component of the pathophysiological mechanism of heparin-induced thrombocytopenia, a sub-study to the HITME study. J. Walenga, PI

bioMerieux, Inc. (Durham, NC) - investigation of the clinical utility of the biphasic waveform of the aPTT in patients admitted to the Emergency Department of Foster G. McGaw Hospital as an early identifier of sepsis/DIC and as a means to monitor patient clinical progress. J. Walenga, PI

Daiichi Pharmaceutical Co, Ltd. (Tokyo, Japan) - development of the synthetic factor Xa inhibitor, DX-9065a, as an antithrombotic drug. J. Walenga, PI

Mitsubishi Pharma Corporation (Tokyo, Japan) - a Phase I study to evaluate the effect of combined argatroban (a thrombin inhibitor) and oral anticoagulants (phenprocoumon and acenocoumarol) on coagulation parameters. J. Walenga, PI

Mitsubishi Pharma Corporation (Tokyo, Japan) - study of the role of nitric oxide up regulation by the thrombin inhibitor argatroban in the mediation of platelet count recovery in patients with HIT. J. Walenga, PI

USDA - Fish skins as a novel source of blood anticoagulant pharmaceuticals: conversion of waste to an economic, value-added product for medical use. W. Jeske, PI

NIH/NHLBI R01 HL70670-01 - Calcium entry and vascular smooth muscle excitation. K.L. Byron, PI

NIH/NHLBI R01 HL67971-01 - Cardioprotection against endotoxins. R. Mestrlil, PI